-
10004259-1A synthetic regioisomer of cannabidiol that fails to elicit either CB1 or CB2 responsiveness and is without psychotropic activity induces endothelium-dependent vasodilation via a CB1/CB2/NO-independent mechanism shows hypotensive activity that
-
10004259-10A synthetic regioisomer of cannabidiol that fails to elicit either CB1 or CB2 responsiveness and is without psychotropic activity induces endothelium-dependent vasodilation via a CB1/CB2/NO-independent mechanism shows hypotensive activity that
-
10004259-25A synthetic regioisomer of cannabidiol that fails to elicit either CB1 or CB2 responsiveness and is without psychotropic activity induces endothelium-dependent vasodilation via a CB1/CB2/NO-independent mechanism shows hypotensive activity that
-
10004259-5A synthetic regioisomer of cannabidiol that fails to elicit either CB1 or CB2 responsiveness and is without psychotropic activity induces endothelium-dependent vasodilation via a CB1/CB2/NO-independent mechanism shows hypotensive activity that
-
10009523-1An internal standard for the quantification of CAY10429 by GC- or LC-MS.
-
10009523-100An internal standard for the quantification of CAY10429 by GC- or LC-MS.
-
10009523-5An internal standard for the quantification of CAY10429 by GC- or LC-MS.
-
10009523-500An internal standard for the quantification of CAY10429 by GC- or LC-MS.
-
10005019-1An HDAC inhibitor with an IC50 value of 30 µM when tested in HeLa cell nuclear extracts using 200 µM acetylated fluorometric substrate.
-
10005019-10An HDAC inhibitor with an IC50 value of 30 µM when tested in HeLa cell nuclear extracts using 200 µM acetylated fluorometric substrate.
-
10005019-25An HDAC inhibitor with an IC50 value of 30 µM when tested in HeLa cell nuclear extracts using 200 µM acetylated fluorometric substrate.
-
10005019-5An HDAC inhibitor with an IC50 value of 30 µM when tested in HeLa cell nuclear extracts using 200 µM acetylated fluorometric substrate.